CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

TitleCCL5 as a potential immunotherapeutic target in triple-negative breast cancer.
Publication TypeJournal Article
Year of Publication2013
AuthorsLv D, Zhang Y, Kim H-J, Zhang L, Ma X
JournalCell Mol Immunol
Date Published2013 Jul
KeywordsAnimals, Antineoplastic Agents, Biomarkers, Breast Neoplasms, Chemokine CCL5, Disease Progression, Drug Resistance, Neoplasm, Estrogen Receptor alpha, Female, Humans, Immunotherapy, Models, Animal, Receptor, erbB-2, Receptors, Progesterone

Breast cancer (BC) is a leading cause of mortality among women in the world. To date, a number of molecules have been established as disease status indicators and therapeutic targets. The best known among them are estrogen receptor-α (ER-α), progesterone receptor (PR) and HER-2/neu. About 15%-20% BC patients do not respond effectively to therapies targeting these classes of tumor-promoting factors. Thus, additional targets are strongly and urgently sought after in therapy for human BCs negative for ER, PR and HER-2, the so-called triple-negative BC (TNBC). Recent clinical work has revealed that CC chemokine ligand 5 (CCL5) is strongly associated with the progression of BC, particularly TNBC. How CCL5 contributes to the development of TNBC is not well understood. Experimental animal studies have begun to address the mechanistic issue. In this article, we will review the clinical and laboratory work in this area that has led to our own hypothesis that targeting CCL5 in TNBCs will have favorable therapeutic outcomes with minimal adverse impact on the general physiology.

Alternate JournalCell Mol Immunol
PubMed ID23376885
PubMed Central IDPMC4003203

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587